{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T17:58:19Z","timestamp":1794592699266,"version":"4.9.1"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T00:00:00Z","timestamp":1768262400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T00:00:00Z","timestamp":1768262400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["INV-001727"],"award-info":[{"award-number":["INV-001727"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006492","name":"Division of Intramural Research, National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["AI000693"],"award-info":[{"award-number":["AI000693"]}],"id":[{"id":"10.13039\/100006492","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Linezolid, an oxazolidinone, is a cornerstone of treatment regimens for highly drug-resistant tuberculosis but cannot be used in drug-susceptible disease because of toxicity. This toxicity results from inhibition of mammalian mitochondrial protein synthesis. Here we show the development of a new oxazolidinone, MK-7762, with antitubercular activity that is better than linezolid and limited mitochondrial protein synthesis inhibition. The cryogenic electron microscopy structure of the stalled mycobacterial ribosome with MK-7762 revealed the basis for this selectivity. BALB\/c mouse models of disease showed MK-7762 reduced lung bacterial burden by a 3-log-fold decrease in an acute model (\n                    <jats:italic>N<\/jats:italic>\n                    \u2009=\u200918) and a 2-log-fold decrease in chronically infected animals (\n                    <jats:italic>N<\/jats:italic>\n                    \u2009=\u200918). MK-7762 showed lesion penetration similar to linezolid in C3HeB\/FeJ mice. MK-7762 had pharmacokinetic properties predicting low once-daily doses in humans and a favorable 14-day preclinical safety profile in Wistar Han rats (\n                    <jats:italic>N<\/jats:italic>\n                    \u2009=\u200930) and Beagle dogs (\n                    <jats:italic>N<\/jats:italic>\n                    \u2009=\u20096). Four-month safety studies in both rats (\n                    <jats:italic>N<\/jats:italic>\n                    \u2009=\u200920) and dogs (\n                    <jats:italic>N<\/jats:italic>\n                    \u2009=\u200924) showed no changes in hematology parameters at exposures well above the 100-mg predicted human dose. These data will enable MK-7762 to be explored as a component of new tuberculosis treatment combinations for all forms of the disease.\n                  <\/jats:p>","DOI":"10.1038\/s41591-025-04164-x","type":"journal-article","created":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T10:01:47Z","timestamp":1768298507000},"page":"553-560","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Discovery and development of a new oxazolidinone with reduced toxicity for the treatment of tuberculosis"],"prefix":"10.1038","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-6140-6499","authenticated-orcid":false,"given":"Brendan M.","family":"Crowley","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4333-206X","authenticated-orcid":false,"given":"Helena I.","family":"Boshoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0114-1254","authenticated-orcid":false,"given":"Aidan","family":"Boving","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vee Y.","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianghai","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Forrest","family":"Hoyt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Randy R.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Ehrhart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-3739-1119","authenticated-orcid":false,"given":"Christopher W.","family":"Boyce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Young","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe G.","family":"Nantermet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lihu","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald E.","family":"Painter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily B.","family":"Corcoran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason L.","family":"Hoar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0895-1110","authenticated-orcid":false,"given":"Sangmi","family":"Oh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David L.","family":"Holtzman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Micha","family":"Levi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aparna","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monicah A.","family":"Otieno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Zimmerman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8655-2065","authenticated-orcid":false,"given":"Firat","family":"Kaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa M.","family":"Massoudi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle E.","family":"Ramey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allison A.","family":"Bauman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne J.","family":"Lenaerts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7157-4034","authenticated-orcid":false,"given":"Gregory T.","family":"Roberston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9470-5009","authenticated-orcid":false,"given":"V\u00e9ronique","family":"Dartois","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles D.","family":"Wells","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2927-270X","authenticated-orcid":false,"suffix":"III","given":"Clifton E.","family":"Barry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5521-0206","authenticated-orcid":false,"given":"David B.","family":"Olsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,13]]},"reference":[{"key":"4164_CR1","unstructured":"World Health Organization. Global Tuberculosis Report 2023 (2023)."},{"key":"4164_CR2","doi-asserted-by":"publisher","unstructured":"Motta, I. et al. Recent advances in the treatment of tuberculosis. Clin. Microbiol. Infect. https:\/\/doi.org\/10.1016\/j.cmi.2023.07.013 (2023).","DOI":"10.1016\/j.cmi.2023.07.013"},{"key":"4164_CR3","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1164\/rccm.202202-0393ED","volume":"205","author":"C Lange","year":"2022","unstructured":"Lange, C., Barry, C. E. III & Horsburgh, C. R. Jr. Treatments of multidrug-resistant tuberculosis: light at the end of the tunnel. Am. J. Respir. Crit. Care Med. 205, 1142\u20131144 (2022).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"4164_CR4","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.1056\/NEJMoa1201964","volume":"367","author":"M Lee","year":"2012","unstructured":"Lee, M. et al. Linezolid for treatment of chronic extensively drug-resistant tuberculosis. N. Engl. J. Med. 367, 1508\u20131518 (2012).","journal-title":"N. Engl. J. Med."},{"key":"4164_CR5","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1056\/NEJMc1500286","volume":"373","author":"M Lee","year":"2015","unstructured":"Lee, M. et al. Linezolid for XDR-TB\u2013final study outcomes. N. Engl. J. Med. 373, 290\u2013291 (2015).","journal-title":"N. Engl. J. Med."},{"key":"4164_CR6","doi-asserted-by":"publisher","first-page":"2331","DOI":"10.1056\/NEJMoa2117166","volume":"387","author":"BT Nyang\u2019wa","year":"2022","unstructured":"Nyang\u2019wa, B. T. et al. A 24-week, all-oral regimen for rifampin-resistant tuberculosis. N. Engl. J. Med. 387, 2331\u20132343 (2022).","journal-title":"N. Engl. J. Med."},{"key":"4164_CR7","unstructured":"World Health Organization. WHO consolidated guidelines on tuberculosis. Module 4: treatment - drug-resistant tuberculosis treatment, 2022 update (2022)."},{"key":"4164_CR8","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1056\/NEJMoa1901814","volume":"382","author":"F Conradie","year":"2020","unstructured":"Conradie, F. et al. Treatment of highly drug-resistant pulmonary tuberculosis. N. Engl. J. Med. 382, 893\u2013902 (2020).","journal-title":"N. Engl. J. Med."},{"key":"4164_CR9","doi-asserted-by":"publisher","first-page":"2042","DOI":"10.1128\/AAC.01411-05","volume":"50","author":"EE McKee","year":"2006","unstructured":"McKee, E. E., Ferguson, M., Bentley, A. T. & Marks, T. A. Inhibition of mammalian mitochondrial protein synthesis by oxazolidinones. Antimicrob. Agents Chemother. 50, 2042\u20132049 (2006).","journal-title":"Antimicrob. Agents Chemother."},{"key":"4164_CR10","doi-asserted-by":"publisher","first-page":"2305","DOI":"10.1056\/NEJM200511243532123","volume":"353","author":"A Soriano","year":"2005","unstructured":"Soriano, A., Miro, O. & Mensa, J. Mitochondrial toxicity associated with linezolid. N. Engl. J. Med. 353, 2305\u20132306 (2005).","journal-title":"N. Engl. J. Med."},{"key":"4164_CR11","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1016\/j.ebiom.2015.09.051","volume":"2","author":"T Song","year":"2015","unstructured":"Song, T. et al. Linezolid trough concentrations correlate with mitochondrial toxicity-related adverse events in the treatment of chronic extensively drug-resistant tuberculosis. EBioMedicine 2, 1627\u20131633 (2015).","journal-title":"EBioMedicine"},{"key":"4164_CR12","doi-asserted-by":"publisher","first-page":"2903","DOI":"10.1128\/AAC.47.9.2903-2913.2003","volume":"47","author":"JC Betts","year":"2003","unstructured":"Betts, J. C. et al. Signature gene expression profiles discriminate between isoniazid-, thiolactomycin-, and triclosan-treated Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 47, 2903\u20132913 (2003).","journal-title":"Antimicrob. Agents Chemother."},{"key":"4164_CR13","doi-asserted-by":"publisher","first-page":"e10069","DOI":"10.1371\/journal.pone.0010069","volume":"5","author":"NK Dutta","year":"2010","unstructured":"Dutta, N. K., Mehra, S. & Kaushal, D. A Mycobacterium tuberculosis sigma factor network responds to cell-envelope damage by the promising anti-mycobacterial thioridazine. PLoS ONE 5, e10069 (2010).","journal-title":"PLoS ONE"},{"key":"4164_CR14","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.tube.2003.12.005","volume":"84","author":"SJ Waddell","year":"2004","unstructured":"Waddell, S. J. et al. The use of microarray analysis to determine the gene expression profiles of Mycobacterium tuberculosis in response to anti-bacterial compounds. Tuberculosis 84, 263\u2013274 (2004).","journal-title":"Tuberculosis"},{"key":"4164_CR15","doi-asserted-by":"publisher","unstructured":"Bibel, B. et al. Context-specific inhibition of mitochondrial ribosomes by phenicol and oxazolidinone antibiotics. Nucleic Acids Res. https:\/\/doi.org\/10.1093\/nar\/gkaf046 (2025).","DOI":"10.1093\/nar\/gkaf046"},{"key":"4164_CR16","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1038\/s41594-022-00723-9","volume":"29","author":"K Tsai","year":"2022","unstructured":"Tsai, K. et al. Structural basis for context-specific inhibition of translation by oxazolidinone antibiotics. Nat. Struct. Mol. Biol. 29, 162\u2013171 (2022).","journal-title":"Nat. Struct. Mol. Biol."},{"key":"4164_CR17","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1021\/acsptsci.0c00041","volume":"3","author":"A Wright","year":"2020","unstructured":"Wright, A. et al. Characterization of the core ribosomal binding region for the oxazolidone family of antibiotics using Cryo-EM. ACS Pharmacol. Transl. Sci. 3, 425\u2013432 (2020).","journal-title":"ACS Pharmacol. Transl. Sci."},{"key":"4164_CR18","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1126\/science.abc7782","volume":"370","author":"N Desai","year":"2020","unstructured":"Desai, N. et al. Elongational stalling activates mitoribosome-associated quality control. Science 370, 1105\u20131110 (2020).","journal-title":"Science"},{"key":"4164_CR19","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1038\/nm.3937","volume":"21","author":"B Prideaux","year":"2015","unstructured":"Prideaux, B. et al. The association between sterilizing activity and drug distribution into tuberculosis lesions. Nat. Med. 21, 1223\u20131227 (2015).","journal-title":"Nat. Med."},{"key":"4164_CR20","doi-asserted-by":"publisher","unstructured":"Zimmerman, M., Blanc, L., Chen, P. Y., Dartois, V. & Prideaux, B. Spatial quantification of drugs in pulmonary tuberculosis lesions by laser capture microdissection liquid chromatography mass spectrometry (LCM-LC\/MS). J Vis. Exp. https:\/\/doi.org\/10.3791\/57402 (2018).","DOI":"10.3791\/57402"},{"key":"4164_CR21","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1242\/dmm.019513","volume":"8","author":"JP Lanoix","year":"2015","unstructured":"Lanoix, J. P., Lenaerts, A. J. & Nuermberger, E. L. Heterogeneous disease progression and treatment response in a C3HeB\/FeJ mouse model of tuberculosis. Dis. Model Mech. 8, 603\u2013610 (2015).","journal-title":"Dis. Model Mech."},{"key":"4164_CR22","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1159\/000048479","volume":"45","author":"WW Yew","year":"1999","unstructured":"Yew, W. W. Directly observed therapy, short-course: the best way to prevent multidrug-resistant tuberculosis. Chemotherapy 45, 26\u201333 (1999).","journal-title":"Chemotherapy"},{"key":"4164_CR23","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00190-24","volume":"68","author":"S Simeon","year":"2024","unstructured":"Simeon, S., Garcia-Cremades, M., Savic, R. & Solans, B. P. Pharmacokinetic-pharmacodynamic modeling of tuberculosis time to positivity and colony-forming unit to assess the response to dose-ranging linezolid. Antimicrob. Agents Chemother. 68, e0019024 (2024).","journal-title":"Antimicrob. Agents Chemother."},{"key":"4164_CR24","doi-asserted-by":"publisher","unstructured":"Alghamdi, W. A. et al. Population pharmacokinetics of linezolid in tuberculosis patients: dosing regimen simulation and target attainment analysis. Antimicrob. Agents Chemother. https:\/\/doi.org\/10.1128\/AAC.01174-20 (2020).","DOI":"10.1128\/AAC.01174-20"},{"key":"4164_CR25","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/nmeth.4169","volume":"14","author":"A Punjani","year":"2017","unstructured":"Punjani, A., Rubinstein, J. L., Fleet, D. J. & Brubaker, M. A. cryoSPARC: algorithms for rapid unsupervised cryo-EM structure determination. Nat. Methods 14, 290\u2013296 (2017).","journal-title":"Nat. Methods"},{"key":"4164_CR26","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1002\/pro.3943","volume":"30","author":"EF Pettersen","year":"2021","unstructured":"Pettersen, E. F. et al. UCSF ChimeraX: structure visualization for researchers, educators, and developers. Protein Sci. 30, 70\u201382 (2021).","journal-title":"Protein Sci."},{"key":"4164_CR27","doi-asserted-by":"publisher","first-page":"2126","DOI":"10.1107\/S0907444904019158","volume":"60","author":"P Emsley","year":"2004","unstructured":"Emsley, P. & Cowtan, K. Coot: model-building tools for molecular graphics. Acta Crystallogr. D Biol. Crystallogr. 60, 2126\u20132132 (2004).","journal-title":"Acta Crystallogr. D Biol. Crystallogr."},{"key":"4164_CR28","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1107\/S0907444909052925","volume":"66","author":"PD Adams","year":"2010","unstructured":"Adams, P. D. et al. PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr. D Biol. Crystallogr. 66, 213\u2013221 (2010).","journal-title":"Acta Crystallogr. D Biol. Crystallogr."},{"key":"4164_CR29","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1016\/j.tube.2012.07.003","volume":"92","author":"SG Franzblau","year":"2012","unstructured":"Franzblau, S. G. et al. Comprehensive analysis of methods used for the evaluation of compounds against Mycobacterium tuberculosis. Tuberculosis 92, 453\u2013488 (2012).","journal-title":"Tuberculosis"},{"key":"4164_CR30","doi-asserted-by":"publisher","first-page":"1951","DOI":"10.1021\/acsinfecdis.0c00252","volume":"6","author":"JN Akester","year":"2020","unstructured":"Akester, J. N. et al. Synthesis, structure-activity relationship, and mechanistic studies of aminoquinazolinones displaying antimycobacterial activity. ACS Infect. Dis. 6, 1951\u20131964 (2020).","journal-title":"ACS Infect. Dis."},{"key":"4164_CR31","doi-asserted-by":"publisher","first-page":"2284","DOI":"10.1021\/acsomega.0c05589","volume":"6","author":"PC Ray","year":"2021","unstructured":"Ray, P. C. et al. Spirocycle MmpL3 inhibitors with improved hERG and cytotoxicity profiles as inhibitors of Mycobacterium tuberculosis growth. ACS Omega 6, 2284\u20132311 (2021).","journal-title":"ACS Omega"},{"key":"4164_CR32","doi-asserted-by":"publisher","first-page":"2294","DOI":"10.1128\/AAC.49.6.2294-2301.2005","volume":"49","author":"AJ Lenaerts","year":"2005","unstructured":"Lenaerts, A. J. et al. Preclinical testing of the nitroimidazopyran PA-824 for activity against Mycobacterium tuberculosis in a series of in vitro and in vivo models. Antimicrob. Agents Chemother. 49, 2294\u20132301 (2005).","journal-title":"Antimicrob. Agents Chemother."},{"key":"4164_CR33","doi-asserted-by":"publisher","unstructured":"Xu, J. et al. Contribution of pretomanid to novel regimens containing bedaquiline with either linezolid or moxifloxacin and pyrazinamide in murine models of tuberculosis. Antimicrob. Agents Chemother https:\/\/doi.org\/10.1128\/AAC.00021-19 (2019).","DOI":"10.1128\/AAC.00021-19"},{"key":"4164_CR34","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00597-23","volume":"67","author":"ME Ramey","year":"2023","unstructured":"Ramey, M. E. et al. Drug distribution and efficacy of the DprE1 inhibitor BTZ-043 in the C3HeB\/FeJ mouse tuberculosis model. Antimicrob. Agents Chemother. 67, e0059723 (2023).","journal-title":"Antimicrob. Agents Chemother."}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-04164-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-04164-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-04164-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,22]],"date-time":"2026-02-22T18:02:39Z","timestamp":1771783359000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-04164-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,13]]},"references-count":34,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["4164"],"URL":"https:\/\/doi.org\/10.1038\/s41591-025-04164-x","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,13]]},"assertion":[{"value":"8 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"B.M.C., R.R.M., C.W.B., K.Y., P.G.N., J.S., L.Y., R.E.P., E.B.C., J.L.H. and D.B.O. are employees of Merck and declare owning stock in the company. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}